Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 14,861 | 1,905 | 3,957 | 7,189 | 5,782 |
| Marketable Securities | 1,970 | 19,030 | 21,762 | 15,862 | 20,752 |
| Receivables | N/A | 80 | 65 | 40 | 14 |
| Other current assets | 348 | 425 | 923 | 1,118 | 933 |
| TOTAL | $17,551 | $21,984 | $27,629 | $24,371 | $27,986 |
| Non-Current Assets | |||||
| PPE Net | 80 | 87 | 232 | 237 | 242 |
| Other Non-Current Assets | 250 | 277 | 303 | 329 | 353 |
| TOTAL | $330 | $364 | $535 | $565 | $595 |
| Total Assets | $17,881 | $22,347 | $28,163 | $24,936 | $28,581 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 735 | 754 | 959 | 1,151 | 781 |
| Accrued Expenses | 1,858 | 1,831 | 1,558 | 2,398 | 2,290 |
| TOTAL | $2,742 | $2,733 | $2,664 | $3,695 | $3,213 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 121 | 150 | 178 | 206 | 232 |
| TOTAL | $121 | $150 | $178 | $206 | $232 |
| Total Liabilities | $2,863 | $2,883 | $2,842 | $3,901 | $3,445 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 6,174 | 5,348 | 5,177 | 4,831 | 4,205 |
| Common Shares | 5 | 5 | 31 | 4 | 25 |
| Retained earnings | -62,723 | -58,128 | -52,350 | -47,872 | -43,593 |
| Other shareholders' equity | 0 | -2 | 166 | 105 | 27 |
| TOTAL | $15,018 | $19,464 | $25,321 | $21,035 | $25,136 |
| Total Liabilities And Equity | $17,881 | $22,347 | $28,163 | $24,936 | $28,581 |